[go: up one dir, main page]

PL3151832T3 - Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności - Google Patents

Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności

Info

Publication number
PL3151832T3
PL3151832T3 PL15803364T PL15803364T PL3151832T3 PL 3151832 T3 PL3151832 T3 PL 3151832T3 PL 15803364 T PL15803364 T PL 15803364T PL 15803364 T PL15803364 T PL 15803364T PL 3151832 T3 PL3151832 T3 PL 3151832T3
Authority
PL
Poland
Prior art keywords
methods
treating secondary
tonic inhibition
secondary insomnia
increasing tonic
Prior art date
Application number
PL15803364T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of PL3151832T3 publication Critical patent/PL3151832T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL15803364T 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności PL3151832T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
PL3151832T3 true PL3151832T3 (pl) 2021-10-25

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15803364T PL3151832T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności
PL18169211T PL3372229T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18169211T PL3372229T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana

Country Status (20)

Country Link
US (11) US20150352085A1 (pl)
EP (3) EP3795156A1 (pl)
JP (4) JP2017516868A (pl)
AR (1) AR100772A1 (pl)
AU (4) AU2015269667B2 (pl)
CA (1) CA2950845C (pl)
CY (2) CY1124366T1 (pl)
DK (2) DK3151832T3 (pl)
ES (2) ES2875742T3 (pl)
HR (2) HRP20210901T1 (pl)
HU (2) HUE055400T2 (pl)
IL (2) IL249287B (pl)
LT (2) LT3151832T (pl)
MX (2) MX380868B (pl)
PL (2) PL3151832T3 (pl)
PT (2) PT3151832T (pl)
RS (2) RS62006B1 (pl)
SI (2) SI3151832T1 (pl)
SM (2) SMT202100340T1 (pl)
WO (1) WO2015187851A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3151832T3 (pl) 2014-06-06 2021-10-25 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
CN119112906A (zh) 2016-08-11 2024-12-13 奥维德医疗公司 用于治疗癫痫性紊乱的方法和组合物
KR20190086709A (ko) * 2016-11-22 2019-07-23 오비드 테라퓨틱스 인크. 가복사돌로 주의력 결핍/과잉행동 장애를 치료하는 방법들
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
MX2021005992A (es) * 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
MX2022000663A (es) * 2019-07-15 2022-02-16 Ovid Therapeutics Inc Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
KR20220114572A (ko) * 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. 1p36 결실 증후군의 치료적 치료를 위한 가복사돌
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
AU2005229493A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP5909750B2 (ja) 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
PL3151832T3 (pl) 2014-06-06 2021-10-25 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności
BR112018000933A2 (pt) * 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
AU2015269667B2 (en) 2020-07-30
HRP20210901T1 (hr) 2021-09-17
US20170087133A1 (en) 2017-03-30
SMT202100343T1 (it) 2021-07-12
AU2022200085A1 (en) 2022-02-03
SMT202100340T1 (it) 2021-07-12
HUE055400T2 (hu) 2021-11-29
JP2017516868A (ja) 2017-06-22
CY1124366T1 (el) 2022-07-22
US9339495B2 (en) 2016-05-17
PT3151832T (pt) 2021-06-15
AU2015269667A1 (en) 2016-12-22
WO2015187851A1 (en) 2015-12-10
MX380868B (es) 2025-03-12
MX2016016136A (es) 2017-07-05
AR100772A1 (es) 2016-11-02
US20230051859A1 (en) 2023-02-16
CA2950845A1 (en) 2015-12-10
JP2020063264A (ja) 2020-04-23
HRP20210902T1 (hr) 2021-09-17
US20150352085A1 (en) 2015-12-10
US20180015076A1 (en) 2018-01-18
IL249287A0 (en) 2017-02-28
IL268960B (en) 2021-05-31
US9446028B2 (en) 2016-09-20
US9744159B2 (en) 2017-08-29
SI3372229T1 (sl) 2021-09-30
CY1124368T1 (el) 2022-07-22
US20170273956A1 (en) 2017-09-28
RS62006B1 (sr) 2021-07-30
US20170071917A1 (en) 2017-03-16
IL249287B (en) 2021-03-25
DK3372229T3 (da) 2021-06-14
US20160038469A1 (en) 2016-02-11
JP2021178836A (ja) 2021-11-18
EP3151832B1 (en) 2021-03-24
DK3151832T3 (da) 2021-06-14
EP3151832A1 (en) 2017-04-12
AU2020217342B2 (en) 2021-10-07
RS62007B1 (sr) 2021-07-30
US20180303805A1 (en) 2018-10-25
EP3151832A4 (en) 2018-01-17
PT3372229T (pt) 2021-06-17
EP3372229B1 (en) 2021-03-24
MX2020012404A (es) 2022-04-11
US20220016091A1 (en) 2022-01-20
IL268960A (en) 2019-10-31
ES2876350T3 (es) 2021-11-12
ES2875742T3 (es) 2021-11-11
US9801864B2 (en) 2017-10-31
US11278529B2 (en) 2022-03-22
JP2023123442A (ja) 2023-09-05
CA2950845C (en) 2023-04-25
US20250025448A1 (en) 2025-01-23
EP3795156A1 (en) 2021-03-24
LT3151832T (lt) 2021-07-12
US20160228418A1 (en) 2016-08-11
SI3151832T1 (sl) 2021-08-31
EP3372229A1 (en) 2018-09-12
HUE055155T2 (hu) 2021-11-29
AU2024202604A1 (en) 2024-05-09
PL3372229T3 (pl) 2021-10-04
AU2020217342A1 (en) 2020-08-27
LT3372229T (lt) 2021-07-12

Similar Documents

Publication Publication Date Title
IL249287B (en) Methods for increasing tonic inhibition and treating secondary insomnia
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
ZA202006746B (en) Methods of treatment
GB2592821B (en) Modified cells and methods of therapy
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
IL259801A (en) ezh2 inhibitors and methods of using them
IL267291A (en) Actonucleotidase inhibitors and methods of using them
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
IL251759A0 (en) Preparations and methods for treating insomnia
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
PT3233071T (pt) Método de tratamento ou prevenção de doenças mediadas por ras
IL272092A (en) Methods for treating changes in behavior
IL256181A (en) Means and methods for treatment of b-cell malignancies
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201605127D0 (en) Composition and methods of treatment
PT3268376T (pt) Inibidores de enolase e métodos de tratamento com os mesmos
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201702189D0 (en) Theory of time and energy
GB201510576D0 (en) Implants and methods of forming thereof
GB201418640D0 (en) Agents and methods for treatment of cancer